News | November 01, 2021
GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Cipla has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
